The new antiepileptic drugs and women: Efficacy, reproductive health, pregnancy, and fetal outcome

Epilepsia

Volumn 37, Issue SUPPL. 6, 1996, Pages

  Morrell, Martha J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticonvulsants; Drug induced abnormalities; Epilepsy; Folic acid deficiency; Pregnancy

Indexed keywords

ANTICONVULSIVE AGENT; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; TIAGABINE; TOPIRAMATE; VIGABATRIN;

ANTICONVULSANT THERAPY; CONFERENCE PAPER; CONGENITAL MALFORMATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; FOLIC ACID DEFICIENCY; HUMAN; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; STEROID METABOLISM; TERATOGENICITY; TREATMENT PLANNING;

EID: 0029807158     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb06037.x     Document Type: Conference Paper

References (109)

1. Merkatz RB, Temple R, Sobel S, and Working Group on Women in Clinical Trials. Women in clinical trials of new drugs: a change in Food and Drug Administration Policy. N Engl J Med 1993;329:292-4.
2. Food and Drug Administration/Department of Health and Human Services. Guidelines for the study and evaluation of gender differences in the clinical evaluation of drugs. Fed Regist 1993;58(139):39406-16.
3. Garofalo E, Eardley D, Koto E, LaMoreaux L. The effectiveness of gabapentin (Neurontin) stratified by gender. Epilepsia 1994;35(suppl 7):69.
4. Data on file. Glaxo Wellcome CNS Clinical Research. Research Triangle Park, NC, 1996.
5. Pledger G, Reife R, Lim P, Karim R. Overview of topiramate efficacy from adjunctive therapy trials. Epilepsia 1995;36(suppl 3):S150.
6. Data on file. Hoechst-Roussel Pharmaceuticals. Somerville, NJ, 1996.
7. Valimaki M, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994;9:631-7.
8. Sheth R, Wesolowski C, Jacob J, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-62.
9. Chung S, Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994;16:382-5.
10. Bogliun G, Beghi E, Crespi V, Delodovick L, d'Amico P. Anticonvulsant drugs and bone metabolism. Acta Neurol Scand 1986;74:284-8.
11. Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med 1986;230:569-77.
12. Marcus R. Secondary forms of osteoporosis. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:889-904.
13. Perrucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987;33:139-44.
14. Webber MP, Hauser WA, Ottman R, Annegers JF. Fertility in persons with epilepsy: 1935-1974. Epilepsia 1986;27:746-52.
15. Dansky LV, Andermann E, Andermann F. Marriage and fertility in epileptic patients. Epilepsia 1980;21:261-71.
16. Isojarvi JIT, Laatikainen TJ, Pakarinen AJ, Juntunen KTS, Myllylä VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-8.
17. Cummings LN, Giudice L, Morrell MJ. Ovulatory function in epilepsy. Epilepsia 1995;36:355-9.
18. Morrell MJ, Guldner G. Self-reported sexual function and sexual arousability in women with epilepsy. Epilepsia 1994;35(suppl 8):56.
19. Drislane FW, Coleman AE, Schomer DL, et al. Altered pulsatile secretion of luteinizing hormone in women with epilepsy. Neurology 1994;44:306-10.
20. Meo R, Bilo L, Nappi C, et al. Derangement of the hypothalamic GnRH pulse generator in women with epilepsy. Seizure 1993;2:241-52.
21. Bilo L, Meo R, Valentino R, Buscaino GA, Straino S, Nappi C. Abnormal pattern of luteinizing hormone pulsability in women with epilepsy. Fertility 1991;55:705-11.
22. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43:341-6.
23. Franchesi M, Perego L, Cavagnini F, et al. Effects of long-term antiepileptic therapy in the hypothalamic-pituitary axis in man. Epilepsia 1984;25:46-52.
24. Rodin E, Subramanian MG, Gilroy J. Investigation of sex hormones in male epileptic patients. Epilepsia 1984;25:690-4.
25. Spark RF, Willis CA, Royal H. Hypogonadism, hyperprolactinemia and temporal lobe epilepsy in hyposexual men. Lancet 1984;1:413-7.
26. Isojarvi JIT, Repo M, Parkarinen AJ, Lukkarinen O, Myllylä VV. Carbamazepine, phenytoin, sex hormones, and sexual function in men with epilepsy. Epilepsia 1995;36:366-70.
27. Isojarvi JIT, Pakarinen AJ, Rautio A, Pelkonen O, Myllylä VV. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur J Clin Pharmacol 1995;47:461-4.
28. Coulam CB, Annegers JF. Do oral anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979;20:519-26.
29. Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA 1986;256:238-40.
30. Sonnen AEH. Oxcarbazepine and oral contraceptives. Acta Neurol Scand 1990;82(suppl 133):37.
31. Jensen PK, Saano V, Haring P, Svenstrup B, Merge GP. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992;33:1149-52.
32. Data on file. Ortho-McNeil Pharmaceuticals. Raritan, NJ, 1996.
33. Eldon MA, Underwood BA, Randinitis EJ, Posvar EL, Sedman AJ. Lack of effect of gabapentin on the pharmacokinetics of a norethindrone acetate/ethanol estradiol-containing oral contraceptive. Neurology 1993;43(suppl 2):A307-8.
34. Data on file. Abbott Laboratories. Abbott Park, IL, 1996.
35. Holdich T, Whiteman P, Orme M, Back D, Ward S. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill. Epilepsia 1991;32(suppl 1):96.
36. Haukkamaa M. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant therapy. Contraception 1986;33:559-65.
37. Odlind V, Olsson SE. Enhanced metabolism of levonorgestrel during phenytoin treatment in a women with Norplant implants. Contraception 1986;33:257-61.
38. Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology 1992;42(suppl 5):12-6.
39. Battino D, Granata T, Binelli S, et al. Intrauterine growth in the offspring of epileptic mothers. Acta Neurol Scand 1992;86:555-7.
40. Perez B, Gorodisch S, Casavilla F, Maruffo C. Ultrastructure of the human liver at the end of normal pregnancy. Am J Obstet Gynecol 1971;110:428-31.
41. Cooney AH. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 1967;9:317-66.
42. Tomson T, Lindbom U, Ekquist B, Sundquist A. Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia 1994;35:131-5.
43. Tomson T, Lindbom U, Ekquist B, Sundquist A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 1994;35:122-30.
44. Battino D, Binelli S, Bossi L, et al. Monitoring of antiepileptic drugs and hormones in pregnant epileptic women. In: Porter RJ, Mattson RH, Ward AA, Jr, Dam M, eds. XVth Epilepsy International symposium. New York: Raven Press, 1984:227-32 (Advances in epileptology, vol. 15).
45. Battino D, Binelli S, Bossi L, et al. Monitoring of antiepileptic drugs and hormones in pregnant epileptic women. In: Porter RJ, Mattson RH, Ward AA, Jr, Dam M, eds. XVth Epilepsy International symposium. New York: Raven Press, 1984:227-32 (Advances in epileptology, vol. 15).
46. Yerby MS, Cawthon ML. Infant mortality of infants of mothers with epilepsy. Ann Neurol 1994;36:330-3.
47. Yerby MS, Koepsell T, Daling J. Pregnancy complications and outcomes in a cohort of women with epilepsy. Epilepsia 1985;26:631-5.
48. Minkoff H, Schaffer RM, Delke I, Grunebaum AN. Diagnosis of intracranial hemorrhage in utero after a maternal seizure. Obstet Gynecol 1985;64(suppl 3):22S-4S.
49. Gaily EK, Granstrom ML, Hiilesmaa VK, Bardy AH. Head circumference in children of epileptic mothers: contributions of drug exposure and genetic background. Epilepsy Res 1990;5:217-22.
50. Gaily E, Kantola-Sorsa E, Granstrom ML. Intelligence of children of epileptic mothers. J Pediatr 1988;113:677-84.
51. Nelson KB, Ellenberg JH. Maternal seizure disorder, outcome of pregnancy, and neurologic abnormalities in the children. Neurology 1982;32:1247-54.
52. Losche G, Steinhausen HC, Koch S, Helge H. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr 1994;83:961-6.
53. Granstrom ML, Gaily E. Psychomotor development in children of mothers with epilepsy. Neurology 1992;42:144-8.
54. Ransom BR, Elmore JG. Effects of antiepileptic drugs on the developing nervous system. In: Smith DB, Treiman DM, Trimble MR, eds. Neurobehavioral problems in epilepsy. New York: Raven Press, 1991:225-37 (Advances in neurology, vol. 55).
55. Ransom BR, Elmore JG. Effects of antiepileptic drugs on the developing nervous system. In: Smith DB, Treiman DM, Trimble MR, eds. Neurobehavioral problems in epilepsy. New York: Raven Press, 1991:225-37 (Advances in neurology, vol. 55).
56. Gaily E, Kantola-Sorsa E, Granstrom ML. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol 1990;32:403-14.
57. German J, Kowal A, Ellers KH. Trimethadione and human teratogenesis. Teratology 1970;3:349-62.
58. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975;87:285-90.
59. Seip M. Growth retardation, dysmorphic facies and minor malformations following massive exposure to phenobarbitone in utero. Acta Paediatr Scand 1976;65:617-21
60. Rudd NL, Freedom RM. A possible primidone embryopathy. J Pediatr 1979;94:835-7.
61. DiLiberti JH, Farndon PA, Dennis NR, Curry CJR. The fetal valproate syndrome. Am J Med Genet 1984;19:473-81.
62. Laegrid L, Olegard R, Walström J, Conradi N. Teratogenic effects of benzodiazepine use during pregnancy. J Pediatr 1989;114:126-31.
63. Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989;320:1661-6.
64. Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning epidemiologic and experimen- tal findings spanning three decades; two human studies. Reprod Toxicol 1991;5:301-35.
65. Andermann E, Kaneko S, Battino D, and the International Collaborative Epilepsy and Pregnancy Group. Collaborative International Prospective Study on congenital malformations in children of mothers with epilepsy. Neurology 1996;46:A111.
66. Friis ML. Facial clefts and congenital heart defects in children of parents with epilepsy: genetic and environmental etiologic factors. Acta Neurol Scand 1989;79:433-59.
67. Annegers JF, Hauser WA, Elveback LR, Anderson VE, Kurland LT. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. Int J Epidemiol 1978;7:241-7.
68. Omtzigt JGC, Los FJ, Grobee DE, et al. The risk of spina bifida aperta after first trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(suppl 5):119-25.
69. Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1986;1:1392-3.
70. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-7.
71. Steegers-Theunissen RPM, Renier WO, Borm GF, et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multicentre prospective study. Epilepsy Res 1994;18:261-9.
72. Yerby MS, Leavitt A, Erickson DM, et al. Antiepileptics and the development of congenital anomalies. Neurology 1992;42(suppl 5):132-40.
73. Lindhout D, Omizigt JG, Cornel MC. Spectrum of neuraltube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992;42(suppl 5):111-8.
74. Koch S, Loesche G, Jager-Roman E, et al. Major and minor malformations and antiepileptic drugs. Neurology 1992;42(suppl 5):83-8.
75. Shapiro S, Slone D, Hartz SC, et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976;1:272-5.
76. Klepel H, Freitag G. Spina bifida occulta in epilepsy syndromes. Neurology 1992;42(suppl 5):119-20.
77. Finnell RH, Buehler BA, Kerr BM, Ager PL, Levy RH. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology 1992;42:25-31.
78. Wong M, Wells PG. Modulation of embryonic glutathione reductase and phenytoin teratogenicity by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU). J Pharmacol Exp Ther 1989;250:336-42.
79. Buehler BA, Delimont D, van Waes M, Finnell R. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 1990;322:1567-72.
80. Pacifici M, Colizzi C, Guiliani L, Rane A. Cytosolic expoxide hydrolase in fetal and adult human liver. Arch Toxicol 1983;54:331.
81. Strickler SM, Miller MA, Andermann E, et al. Genetic predisposition to phenytoin-induced birth defects. Lancet 1985;2:746-9.
82. Buehler BA, Rao V, Finnell RH. Biochemical and molecular teratology of fetal hydantoin syndrome. Neurol Clin 1994;12:741-8.
83. Jordan RL, Wilson JG, Schumacher HJ. Embryotoxicity of the folate antagonist methotrexate in rats and rabbits. Teratology 1977;15:73-80.
84. Ogawa Y, Kaneko S, Otani K, Fukushima Y. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991;8:75-8.
85. Dansky LV, Andermann E, Rosenblatt D, Sherwin AL, Andermann F. Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Ann Neurol 1987;21:176-82.
86. Wegner C, Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis. Neurology 1992;42(suppl 5):17-24.
87. Mulinare J, Corder JF, Erickson JD. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988;260:3141-5.
88. Milunsky A, Jick H, Jick SS. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1988;262:2847-52.
89. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993;269:1257-61.
90. Laurence KM, James N, Miller MH. Double-blind, randomized controlled trial of folate treatment before conception to prevent the recurrence of neural-tube defects. BMJ 1981;282:1509-11.
91. Czeizel AE, Dudas I. Prevention of the first occurrence of neural tube defects by Periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-5.
92. Medical Research Council Vitamin Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-7.
93. Van Allen MI, Fraser FC, Dallaire L, et al. Recommendations on the use of folic acid supplementation to prevent the recurrence of neural tube defects. Can Med Assoc J 1993;149:1239-43.
94. Centers for Disease Control. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morbid Mortal Rep 1992;41:1-7.
95. Grimes DA. Unplanned pregnancies in the U.S. Obstet Gynecol 1986;67:438-42.
96. Clark N, Fisk N. Minimal compliance with the Department of Health recommendation for routine prophylaxis to prevent fetal neural tube defects. Br J Obstet Gynaecol 1994;101:709-10.
97. Oguni M, Dansky L, Andermann E, Sherwin A, Andermann F. Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain Dev 1992;14:371-80.
98. Kaneko S, Otani K, Fukushima Y. Teratogenicity of anti- epilepsy drugs-analysis of possible risk factors. Epilepsia 1988;29:459-67.
99. Nakane Y, Okuma T, Takahaski R, et al. Multiinstitutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980;21:663-80.
100. Liu H, Delgado M. Interactions of phenobarbital and phenytoin with carbamazepine and its metabolites' concentrations, concentration ratios, and level/dose ratios in epileptic children. Epilepsia 1995;36:249-54.
101. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.
102. Regan CM, Gorman AM, Larsson OM, et al. In vitro screening for anticonvulsant induced teratogenesis in neural primary cultures and cell lines. Int J Dev Neurosci 1990;8:143-50.
103. Mino Y, Mizusawa H, Shiota K. Effects of anticonvulsant drugs on fetal mouse palates cultured in vitro. Reprod Toxicol 1994;8:225-30.
104. Data on file. Parke-Davis, Division of Warner-Lambert Company. Morris Plains, NJ, 1996.
105. Institute of Medicine. Women and health research: ethical and legal issues of including women in clinical trials. February 24, 1994.
106. National Institutes of Health. NIH Guidelines on the inclusion of women and minorities as subjects in clinical research. Fed Regist 1994;59:1408-13.
107. Data on file. Wallace Laboratories. Cranbury, NJ, 1995.
108. Sander JWAS, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res 1992;13:89-92.
109. Data on file. Ciba-Geigy. Summit, NJ, 1996.